DIRA 1.0: Atlas of Drug-induced Rhabdomyolysis

TRIENTINE HYDROCHLORIDE

Classification:Less-DIR concern

Severity Score:1

ADVERSE REACTIONS
Clinical experience with Syprine has been limited. The following adverse reactions have been reported in a clinical study in patients with Wilson's disease who were on therapy with trientine hydrochloride: iron deficiency, systemic lupus erythematosus (see CLINICAL PHARMACOLOGY). In addition, the following adverse reactions have been reported in marketed use: dystonia, muscular spasm, myasthenia gravis.
Syprine is not indicated for treatment of biliary cirrhosis, but in one study of 4 patients treated with trientine hydrochloride for primary biliary cirrhosis, the following adverse reactions were reported: heartburn; epigastric pain and tenderness; thickening, fissuring and flaking of the skin; hypochromic microcytic anemia; acute gastritis; aphthoid ulcers; abdominal pain; melena; anorexia; malaise; cramps; muscle pain; weakness; rhabdomyolysis. A causal relationship of these reactions to drug therapy could not be rejected or established.

Current Drug

Other Drugs

Rhabdomyolysis

42912

Other ADRs

14117229

Odds Ratio = N/A

ATC Code(s): N/A

Active Ingredient:trientine hydrochloride

Active Ingredient UNII:HC3NX54582

Drugbank ID:DB06824

PubChem Compound:5565

CAS Number:112-24-3

Dosage Form(s):capsule

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
C(CNCCNCCN)N

N/A

N/A